AU2001262939A1 - Formulations and use of activated protein c and protein c zymogen for treating hypercoagulable states - Google Patents

Formulations and use of activated protein c and protein c zymogen for treating hypercoagulable states

Info

Publication number
AU2001262939A1
AU2001262939A1 AU2001262939A AU6293901A AU2001262939A1 AU 2001262939 A1 AU2001262939 A1 AU 2001262939A1 AU 2001262939 A AU2001262939 A AU 2001262939A AU 6293901 A AU6293901 A AU 6293901A AU 2001262939 A1 AU2001262939 A1 AU 2001262939A1
Authority
AU
Australia
Prior art keywords
protein
zymogen
formulations
hypercoagulable states
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001262939A
Inventor
Brian Paul Barrett
Charles Jack Fisher
Sau-Chi Betty Yan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of AU2001262939A1 publication Critical patent/AU2001262939A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4866—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
AU2001262939A 2000-05-24 2001-05-14 Formulations and use of activated protein c and protein c zymogen for treating hypercoagulable states Abandoned AU2001262939A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20673300P 2000-05-24 2000-05-24
US60/206,733 2000-05-24
PCT/US2001/011771 WO2001089558A2 (en) 2000-05-24 2001-05-14 Formulations and use of activated protein c and protein c zymogen for treating hypercoagulable states

Publications (1)

Publication Number Publication Date
AU2001262939A1 true AU2001262939A1 (en) 2001-12-03

Family

ID=22767701

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001262939A Abandoned AU2001262939A1 (en) 2000-05-24 2001-05-14 Formulations and use of activated protein c and protein c zymogen for treating hypercoagulable states

Country Status (6)

Country Link
US (1) US7087578B2 (en)
EP (1) EP1289543A2 (en)
JP (1) JP2004511428A (en)
AU (1) AU2001262939A1 (en)
CA (1) CA2410567A1 (en)
WO (1) WO2001089558A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001290553A1 (en) * 2000-09-18 2002-04-02 Eli Lilly And Company Method for using activated protein c for the treatment of coagulation-associated disorders
AU2003298906A1 (en) * 2002-12-06 2004-06-30 Agennix Incorporated Oral lactoferrin in the treatment of sepsis
WO2005042011A1 (en) * 2003-11-04 2005-05-12 Novo Nordisk A/S Pharmaceutical composition comprising a protein c polypeptide and a blood glucose regulator
WO2008107908A1 (en) * 2007-03-05 2008-09-12 Cadila Healthcare Limited Compositions comprising peg- interferon alpha conjugates and raffinose as cryoprotectant
WO2011106759A1 (en) * 2010-02-26 2011-09-01 The Children's Hospital Of Philadelphia Protein c zymogen and methods of use thereof to prevent cancer metastases
ES2609070T3 (en) * 2013-02-28 2017-04-18 Csl Behring Gmbh Therapeutic agent for amniotic fluid embolism
WO2019143685A1 (en) * 2018-01-16 2019-07-25 Women & Infants Hospital Of Rhode Island Methods and compositions for treating pre-eclampsia
EP4053559A1 (en) * 2021-03-01 2022-09-07 Consorcio Centro de Investigación Biomédica en Red, M.P. (CIBER) Methods for the measurement of protein c and activated protein c

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775624A (en) 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
US4849403A (en) 1985-05-29 1989-07-18 Pentapharm Ag Protein C activator, methods of preparation and use thereof
US5516650A (en) 1985-06-27 1996-05-14 Zymogenetics, Inc. Production of activated protein C
AT399095B (en) 1986-03-27 1995-03-27 Vukovich Thomas Dr METHOD FOR SEPARATING PROTEINS BY MEANS OF GRADIENT ELUTION AND DEVICE FOR IMPLEMENTING THE METHOD
US5175087A (en) 1987-07-06 1992-12-29 Biopool International, Inc. Method of performing tissue plasminogen activator assay
CA1329760C (en) 1987-10-29 1994-05-24 Ted C. K. Lee Plasma and recombinant protein formulations in high ionic strength media
US4877608A (en) 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
US5084274A (en) 1987-11-17 1992-01-28 Scripps Clinic And Research Foundation Inhibition of arterial thrombotic occlusion or thromboembolism
US4992373A (en) 1987-12-04 1991-02-12 Eli Lilly And Company Vectors and compounds for direct expression of activated human protein C
US5009889A (en) 1987-12-31 1991-04-23 Oklahoma Medical Research Foundation Treatment of dysfunctional vascular endothelium using activated protein C
JP2739050B2 (en) 1988-01-28 1998-04-08 ヘキスト薬品工業株式会社 Anticoagulant
JPH01226900A (en) 1988-03-08 1989-09-11 Green Cross Corp:The Method for purifying protein c
DE3823519A1 (en) 1988-07-12 1990-01-18 Basf Ag Process for the purification of activated protein C
GB8819607D0 (en) 1988-08-17 1988-09-21 Wellcome Found Novel combination
US4981952A (en) 1988-10-04 1991-01-01 Eli Lilly And Company Method for the purification of vitamin K-dependent proteins
US5093117A (en) 1989-01-24 1992-03-03 Baxter International Inc. Compositions and method for the treatment or prophylaxis of sepsis or septic shock
US5358932A (en) 1989-12-29 1994-10-25 Zymogenetics, Inc. Hybrid protein C
JPH05506354A (en) 1990-02-09 1993-09-22 ザイモジェネティクス，インコーポレイティド Active protein C with truncated light chain
IL97312A (en) 1990-02-23 1999-01-26 Lilly Co Eli Method for producing a polypeptide in a eukaryotic host cell and recombinant dna vectors containing an improved transcription control unit based on the adenovirus 2 major late promoter used thereto
AT402262B (en) 1991-06-20 1997-03-25 Immuno Ag MEDICINAL ACTIVATED PROTEIN C
US5413732A (en) 1991-08-19 1995-05-09 Abaxis, Inc. Reagent compositions for analytical testing
JP3434326B2 (en) 1992-08-25 2003-08-04 財団法人化学及血清療法研究所 Agent for prevention and treatment of adult respiratory distress syndrome (ARDS)
DE4234295A1 (en) 1992-10-12 1994-04-14 Thomae Gmbh Dr K Carboxylic acid derivatives, medicaments containing these compounds and process for their preparation
US5395923A (en) 1993-02-23 1995-03-07 Haemacure-Biotech, Inc. Process for the obtention of a biological adhesive made of concentrated coagulation factors by "salting-out"
US5453523A (en) 1993-06-16 1995-09-26 Emulsion Technology, Inc. Process for obtaining highly purified phosphatidylcholine
JP2825739B2 (en) 1993-09-20 1998-11-18 帝人株式会社 Acute liver failure treatment
JP2886061B2 (en) 1993-10-29 1999-04-26 財団法人化学及血清療法研究所 Method and composition for stabilizing protein C or activated protein C
JP3043558B2 (en) 1993-10-29 2000-05-22 財団法人化学及血清療法研究所 Preparation of human activated protein C and method for its preparation
JPH07165605A (en) 1993-12-16 1995-06-27 Teijin Ltd Activated protein c vial
NZ270271A (en) 1994-01-05 1996-07-26 Lilly Co Eli Minimizing protein c degradation
JPH08301786A (en) 1995-05-11 1996-11-19 Mochida Pharmaceut Co Ltd Preparation for preventing and treating absorption bone disease
JP3802104B2 (en) 1995-05-31 2006-07-26 財団法人化学及血清療法研究所 Preventive and therapeutic agents for neuropathy associated with spinal cord injury
WO1997020043A1 (en) 1995-11-30 1997-06-05 Zymogenetics, Inc. Protein c production in transgenic animals
NZ337828A (en) 1997-04-28 2001-06-29 Lilly Co Eli Activated protein C formulations having a bulking agent and a salt
HUP0001237A3 (en) 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders

Also Published As

Publication number Publication date
WO2001089558A2 (en) 2001-11-29
EP1289543A2 (en) 2003-03-12
CA2410567A1 (en) 2001-11-29
JP2004511428A (en) 2004-04-15
WO2001089558A3 (en) 2002-09-12
US20030211969A1 (en) 2003-11-13
US7087578B2 (en) 2006-08-08

Similar Documents

Publication Publication Date Title
AU2001277172A1 (en) Bstp-trans protein and related reagents and methods of use thereof
AU2001241474A1 (en) Biosensor compositions and methods of use
AU2001267475A1 (en) Combinations of Enzyme Inhibitor-Containing Preparations and the use thereof
AU2001288249A1 (en) Biosensors and methods for their use
AU2001259758A1 (en) Interleukin-1 inhibitors in the treatment of diseases
AU2001249670A1 (en) Substituted thiazoles and the use thereof as inhibitors of plasminogen activatorinhibitor-1
AU2002230831A1 (en) Compositions of human proteins and method of use thereof
AU2002211389A1 (en) Microfluidic devices and methods of use
AU2001253723A1 (en) Dispersible absorbent products and methods of manufacture and use
AU2002225954A1 (en) Dipeptidylpeptidases and methods of use
AU2002215261A1 (en) Method and arrangement for treatment of fluid
AU2001274817A1 (en) Agents that modulate dna-pk activity and methods of use thereof
HK1053673A1 (en) Methods of protein destabilization and uses thereof
AU2001249389A1 (en) Modified blood clotting factors and methods of use
AU2001278011A1 (en) Bstp-ecg1 protein and related reagents and methods of use thereof
AU2002246808A1 (en) Human nucleic acids and polypeptides and methods of use thereof
AU2002213346A1 (en) Osteopontin-coated surfaces and methods of use
AU2001262939A1 (en) Formulations and use of activated protein c and protein c zymogen for treating hypercoagulable states
AU6887101A (en) Copolymers and methods of treating prion-related diseases
AU2001277202A1 (en) Bstp-ras/rerg protein and related reagents and methods of use thereof
AU2001234544A1 (en) Novel human protein kinases and protein kinase-like enzymes
AU2001234962A1 (en) Mixtures of caspase inhibitors and complement inhibitors and methods of use thereof
AU2001237543A1 (en) Proteins, genes and their use for diagnosis and treatment of schizophrenia
AU2001261496A1 (en) Luxo-sigma54 interactions and methods of use
AU5565401A (en) Materials and methods for the treatment of depression